Skip to main content

ADVERTISEMENT

Dongliang Fu, MD

Original Contribution
11/01/2021
Dr. Fu and colleagues evaluated MACE and hemorrhagic event rates for an antithrombotic regimen using bivalirudin or UFH during PCI in ACS patients.
Dr. Fu and colleagues evaluated MACE and hemorrhagic event rates for an antithrombotic regimen using bivalirudin or UFH during PCI in ACS patients.
Dr. Fu and colleagues evaluated...
11/01/2021
Journal of Invasive Cardiology